TABLE 3.
Associations between EGFR/KRAS mutations and histologic subtypes/mucinous features
| Variable | Mutation, n (%)
|
P-value (overall) |
P-value (pairwise comparison)
|
||||
|---|---|---|---|---|---|---|---|
| Wild-type | EGFR | KRAS | EGFR vs. wild-type | KRAS vs. wild-type | EGFR vs. KRAS | ||
| Histologic subtype | |||||||
| Lepidic predominant group | 72 (55) | 31 (24) | 27 (21) | 0.019 | 0.011 | 0.72 | 0.011 |
| Nonlepidic | 419 (60) | 96 (14) | 177 (26) | ||||
| Acinar | 180 (60) | 54 (18) | 66 (22) | 0.18 | |||
| Nonacinar | 311 (60) | 73 (14) | 138 (26) | ||||
| Papillary | 76 (50) | 29 (19) | 46 (30) | 0.032 | 0.063 | 0.029 | 1.00 |
| Nonpapillary | 415 (62) | 98 (15) | 158 (24) | ||||
| Micropapillary | 49 (63) | 7 (9) | 22 (28) | 0.23 | |||
| Nonmicropapillary | 442 (59) | 120 (16) | 182 (24) | ||||
| Solid | 114 (70) | 6 (4) | 43 (26) | <0.001 | <0.001 | 0.62 | <0.001 |
| Nonsolid | 377 (57) | 121 (18) | 161 (24) | ||||
| Cribriform | 26 (77) | 4 (12) | 4 (12) | 0.11 | |||
| Noncribriform | 465 (59) | 123 (16) | 200 (25) | ||||
| Mucinous feature | |||||||
| Signet-ring cell feature | 35 (56) | 8 (13) | 19 (31) | 0.52 | |||
| Non–signet-ring cell feature | 456 (60) | 119 (16) | 185 (24) | ||||
| Extracellular mucin | 58 (50) | 7 (6) | 51 (44) | <0.001 | 0.050 | <0.001 | <0.001 |
| Nonextracellular mucin | 433 (61) | 120 (17) | 153 (22) | ||||
Lepidic-predominant group includes nonmucinous adenocarcinoma in situ, nonmucinous minimally invasive adenocarcinoma, and lepidic-predominant invasive adenocarcinoma.
Significant P-values are shown in bold.
EGFR, epidermal growth factor receptor